Загрузка...
Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding
BACKGROUND: Conventional phase I algorithms for finding a phase-2 recommended dose (P2RD) based on toxicity alone is problematic because the maximum tolerated dose (MTD) is not necessarily the optimal dose with the most desirable risk–benefit trade-off. Moreover, the increasingly common practice of...
Сохранить в:
| Опубликовано в: : | Ann Oncol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5888967/ https://ncbi.nlm.nih.gov/pubmed/29267863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx795 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|